Extended Data Fig. 3: MTT assay demonstrating that the ARAF-S214P mutation does not enhance proliferation.
From: ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor
There is no increase in proliferation observed in transduced HDLECs from an independent experiment. The contents of triplicate wells (n = 3 independent wells) were collected at the indicated times as described in the Methods. The trend lines connect the means for each transductant at each time point, and the points show the measured values for all data points. This experiment is the second of two representative experiments, as described in Fig. 2f.
